To make good communication choices for their children who are deaf or hard of hearing, hearing parents must develop their understanding of hearing loss.

Pharmaceuticals make symptoms and biological drug targets more visible but can render individual and community suffering less visible.

Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.

If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.

Clinicians can practice disability humility by developing social understandings of disability.

Ari Ne’eman joins Ethics Talk to discuss his article, When Disability is Defined by Behavior, Outcome Measures Should Not promote “Passing”.

Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"

Using social media tools in health-related research involves challenges to confidentiality, privacy, and consent.

Clinicians must advocate for decriminalization of SUDs during pregnancy and for improving access to comprehensive, evidence-based care.

Six recommendations focus on specific actions to help reverse the nation’s opioid epidemic.